

Available SRT Dosimetry Methods/Approaches

George Sgouros, Ph.D.

**Russell H. Morgan Dept of Radiology
& Radiological Science**

**Johns Hopkins University, School of Medicine
Baltimore MD**

Disclosures

Consultant: Bayer, Roche

Scientific Advisory Board: Orano Med

Founder: Radiopharmaceutical Imaging and
Dosimetry (RAPID), LLC




Biomarkers

- **Select patients most likely to respond**
- **Avoid toxicity**
- **Tumor biopsy**
- **Serum sampling**
- **Genetic and epigenetic marker analysis**
- **Must be rigorously qualified/validated retrospectively or in prospective studies**
- **Standardized**
- **Incorporated in the design of clinical trials**

Dosimetry

- Select patients most likely to respond
- Avoid toxicity
- Quantitative imaging
- Breath Sampling
- Genetic data & genetic marker analysis
- Must be rigorously qualified/validated retrospectively or in prospective studies
- Standardized
- Incorporated in the design of clinical trials

Phantoms



Summary of Experience

- RPT dosimetry has used model-based methods appropriate for risk evaluation
- not patient-specific, no accounting for non-uniformity, no accounting for radiobiology
- **did not predict toxicity/efficacy**
- **dosimetry more involved, costly & w/o benefit.**
- **not essential in RPT planning**
- **adopt chemo-based dosing.**

Patient-specific, 3-D dosimetry


3D-Internal Dosimetry (3D-ID)

- Patient specific, using 3-D anatomy and activity data
- Calculates absorbed dose voxel by voxel
- Output dose as mean over chosen volume or DVH




3D-Radiobiological Dosimetry (3D-RD)

- Integrates Monte Carlo calculation
- Radiobiological modeling: absorbed dose → response
- Better predict tumor response and toxicity

3D-RD Flowchart



Patient Simplified model





AA vs AD-based Dosing

AA-based dosing

Escalation Study

- AA level 1, 2, etc
- Assess Tox at each AA level
- Identify AA level for Limiting Tox (AA_{DLT})



AD-based dosing

Tracer Study (imaging)


- Activity Data SPECT or PET
- Anatomy Data CT (or MRI)
- For each patient

Patient-specific Dosimetry


- Calculate AD
- Determine AA for AD level 1, 2, etc

Escalation Study


- Assess Tox at each AD level
- Identify AD level for Dose Limiting Tox (AD_{DLT})



Admin Activity (AA) vs Abs Dose



Treatment Planning Paradigm



PRECISION RPT IMPLEMENTATION




Fig. 1. A simplified approach to precision radiopharmaceutical therapy is illustrated.

Conclusions

- RPT dosimetry is the ideal biomarker
- Mechanism of action is well understood
- Need to overcome prior history – 2nd chance
- Needed measurements are known
- Patient-specific dosimetry tools are available
- Implement standardized, validated activity quantification and dosimetry methods in early phase clinical trials to gather rigorous evidence that dosimetry will improve patient care
- Response data from radiotherapy
- Can measure delivery of the therapeutic agent to tumor targets and to normal organs
- Calculate radiation dose to tumors, normal organs
- Guide escalation protocols and plan treatment